Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004225 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004225 is a Phase 1 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00004225, a Phase 1 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy plus radiation therapy in treating patients who have non-small cell lung cancer.
Interventions
- RADIATION radiation therapy
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004225
The ClinicalTrials.gov registry entry for NCT00004225 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00004225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004225 about?
NCT00004225 is a clinical study titled "Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy plus radiation therapy in treating patients who have ...
What is the current status of trial NCT00004225?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-01.
What interventions are being tested in trial NCT00004225?
The interventions under investigation include: radiation therapy (RADIATION), Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004225?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.